Compared with the control group, the 100 mm3 (at start) group treated with the anti-CTLA-4 antibody (10 mg/kg, biw, ip) on day five showed anti-tumor activity with a statistical difference compared with the vehicle group (***P < 0.001) (the tumor volumes were 23±4 mm3 vs. 2106±205 mm3). The gene discussed is CTLA4; the disease is neoplasm.